Lyell Immunopharma (LYEL) Change in Acquisitions & Divestments (2020 - 2026)

Lyell Immunopharma's Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $54.6 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 64.54% year-over-year to $54.6 million; the TTM figure through Mar 2026 stood at $275.2 million (down 51.97% YoY), while the FY2025 annual figure was $374.7 million, down 31.74% from the prior year.
• Change in Acquisitions & Divestments came in at $54.6 million for Q1 2026 at Lyell Immunopharma, up from $52.9 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $187.1 million in Q2 2023 to a low of $52.9 million in Q4 2025.
• A 5-year average of $121.2 million and a median of $123.7 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments soared 78.24% in 2023 and slumped 64.54% in 2026, its largest moves.
• Lyell Immunopharma's Change in Acquisitions & Divestments stood at $110.9 million in 2022, then jumped by 40.78% to $156.1 million in 2023, then dropped by 20.77% to $123.7 million in 2024, then plunged by 57.23% to $52.9 million in 2025, then advanced by 3.29% to $54.6 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $54.6 million, $52.9 million, and $74.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison